Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KIAA1191 pseudogene 2 (KIAA1191P2) is annotated as a pseudogene in the human genome, meaning it is a DNA sequence related to the protein-coding gene KIAA1191 but does not encode a functional protein[2][5]. Pseudogenes typically arise from duplication or retrotransposition events, and while some can be transcribed, they generally lack biological function and are not subject to selection pressure[6]. KIAA1191P2 has no established role in biological processes, molecular pathways, disease, or drug targeting. It should not be considered a therapeutic target for drug development. If your intent is to identify a therapeutic target, you should instead examine the parental, protein-coding gene **KIAA1191**, which encodes a potential NADPH-dependent oxidoreductase that may influence neuronal processes[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KIAA1191 pseudogene 2 (KIAA1191P2).